Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity
Immunoglobulin (Ig) molecules are composed of heavy and light chains that possess highly variable regions at their amino termini. These variable regions combine to form the antigen recognition site, which can itself be recognized as an antigen, termed the idiotype. B-cell malignancies are clonal proliferations of Ig-producing cells. The idiotypic determinants of the surface Ig can thus serve as a tumor-specific marker for the malignant clone. We and others continue to investigate strategies to induce specific immunity against the idiotypic determinants on the Ig molecule expressed and/or secreted by B-cell malignancies by active immunization. This chapter will summarize the progress in exploiting tumor-derived Ig protein as a tumor-specific antigen for therapeutic vaccine development and the priorities for future investigation.
KeywordsKeyhole Limpet Hemocyanin Myeloma Protein MOPC Tumor Antigen Recognition Site Idiotypic Determinant
Unable to display preview. Download preview PDF.
- 20.Sternas L, Janik JE, Duffey PL, Gocke C, Reynolds CW, Wittes RE, Kwak LW. 1996. Early results of a clinical trial of therapeutic vaccination with Ig idiotype antigen for de novo follicular lymphoma. Blood 88(Suppl l):672a. (abstract)Google Scholar
- 25.Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O’Carroll K, Guarnieri F, Longo DL, Kwak LW. 1996. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-l-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156:3858–3865.PubMedGoogle Scholar